Vericel Corporation

NasdaqGM:VCEL Stock Report

Market Cap: US$1.9b

Vericel Valuation

Is VCEL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VCEL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$1.42
Fair Value
2.4k% overvalued intrinsic discount
7
Number of Analysts

Below Fair Value: VCEL ($34.88) is trading above our estimate of fair value ($1.42)

Significantly Below Fair Value: VCEL is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VCEL?

Key metric: As VCEL is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VCEL. This is calculated by dividing VCEL's market cap by their current revenue.
What is VCEL's PS Ratio?
PS Ratio7.1x
SalesUS$249.12m
Market CapUS$1.86b

Price to Sales Ratio vs Peers

How does VCEL's PS Ratio compare to its peers?

The above table shows the PS ratio for VCEL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13.7x
TWST Twist Bioscience
5.4x14.26%US$2.0b
AUPH Aurinia Pharmaceuticals
6.2x11.86%US$1.7b
BEAM Beam Therapeutics
40.4x47.37%US$2.6b
BCRX BioCryst Pharmaceuticals
2.8x13.76%US$1.5b
VCEL Vericel
7.1x18.52%US$1.9b

Price-To-Sales vs Peers: VCEL is good value based on its Price-To-Sales Ratio (7.1x) compared to the peer average (13.7x).

Price to Sales Ratio vs Industry

How does VCEL's PS Ratio compare vs other companies in the US Biotechs Industry?

152 CompaniesPrice / SalesEstimated GrowthMarket Cap
AMGN Amgen
4.5x2.24%US$157.25b
REGN Regeneron Pharmaceuticals
4.7x7.01%US$67.28b
BIIB Biogen
2.2x-1.19%US$21.86b
INCY Incyte
3.7x2.14%US$17.90b
VCEL 7.1xIndustry Avg. 10.8xNo. of Companies152PS020406080100+
152 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VCEL is good value based on its Price-To-Sales Ratio (7.1x) compared to the US Biotechs industry average (11.4x).

Price to Sales Ratio vs Fair Ratio

What is VCEL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VCEL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.1x
Fair PS Ratio5.8x

Price-To-Sales vs Fair Ratio: VCEL is expensive based on its Price-To-Sales Ratio (7.1x) compared to the estimated Fair Price-To-Sales Ratio (5.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VCEL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$34.88
US$54.14
+55.23%
12.54%US$62.00US$41.00n/a7
Oct ’26US$30.91
US$55.14
+78.40%
9.42%US$62.00US$46.00n/a7
Sep ’26US$36.36
US$53.88
+48.17%
10.96%US$62.00US$45.00n/a8
Aug ’26US$35.63
US$53.88
+51.21%
10.96%US$62.00US$45.00n/a8
Jul ’26US$41.60
US$59.38
+42.73%
7.85%US$67.00US$52.00n/a8
Jun ’26US$41.30
US$59.38
+43.78%
7.85%US$67.00US$52.00n/a8
May ’26US$37.92
US$63.25
+66.80%
9.35%US$72.00US$51.00n/a8
Apr ’26US$43.09
US$65.38
+51.73%
6.26%US$72.00US$60.00n/a8
Mar ’26US$51.29
US$64.57
+25.89%
5.79%US$72.00US$60.00n/a7
Feb ’26US$58.54
US$66.50
+13.60%
5.37%US$72.00US$60.00n/a8
Jan ’26US$54.91
US$64.25
+17.01%
6.91%US$72.00US$56.00n/a8
Dec ’25US$58.14
US$61.50
+5.78%
5.01%US$66.00US$56.00n/a8
Nov ’25US$43.99
US$57.14
+29.90%
3.67%US$60.00US$54.00n/a7
Oct ’25US$40.05
US$57.14
+42.68%
3.67%US$60.00US$54.00US$30.917
Sep ’25US$51.65
US$57.25
+10.84%
3.47%US$60.00US$54.00US$36.368
Aug ’25US$47.52
US$55.86
+17.54%
2.43%US$58.00US$54.00US$35.637
Jul ’25US$45.03
US$55.43
+23.09%
2.13%US$57.00US$53.00US$41.607
Jun ’25US$47.70
US$55.50
+16.35%
2.27%US$57.00US$53.00US$41.306
May ’25US$47.08
US$53.90
+14.49%
5.94%US$57.00US$47.40US$37.926
Apr ’25US$52.90
US$53.07
+0.32%
5.40%US$57.00US$47.40US$43.096
Mar ’25US$44.71
US$52.07
+16.45%
4.44%US$54.00US$47.40US$51.296
Feb ’25US$43.65
US$46.23
+5.92%
6.35%US$51.00US$42.40US$58.546
Jan ’25US$35.61
US$42.58
+19.58%
5.00%US$45.00US$39.00US$54.916
Dec ’24US$35.62
US$42.58
+19.55%
5.00%US$45.00US$39.00US$58.146
Nov ’24US$35.00
US$40.75
+16.43%
9.55%US$44.50US$33.00US$43.996
Oct ’24US$33.52
US$41.70
+24.40%
5.65%US$44.50US$39.00US$40.055
US$54.14
Fair Value
35.6% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/29 05:48
End of Day Share Price 2025/10/29 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vericel Corporation is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeAscendiant Capital Markets LLC
Michael GormanBTIG
Caitlin CroninCanaccord Genuity